HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Protein tethers HIV and Ebola to cells

    A family of proteins that helps viruses, such as HIV and Ebola, enter a cell also can block the release of those viruses. When HIV-1 or any virus infects a cell, it replicates and spreads to other cells. One type of cellular protein—T cell immunoglobulin and mucin domain, or TIM-1—has previously been shown to promote entry of some highly pathogenic viruses into host cells. Researchers have now discovered that the same protein possesses a unique ability to block the release of such viruses. The findings are published in the Proceedings of the National Academy of Sciences. “This is a surprising finding that provides new insights into our understanding of not only HIV infection, but also that of Ebola and other viruses,” says Shan-Lu Liu, associate professor of molecular microbiology and immunology at University of Missouri.

    26 August 2014 | Futurity
  • Zambia: PMTCT Real Life Story

    The pain of living through the loss of three children was enough to discourage Constance Mudenda from ever contemplating parenting. When she was pregnant, her greatest desire was to have a child born free of HIV, and now she will continue to mentor her daughter to ensure she is protected from acquiring HIV.

    21 August 2014 | Times of Zambia
  • HIV drugs 'boost South African life expectancy'

    South Africans are living on average up to 61.2 years compared to 52.2 years nearly 10 years ago, mainly thanks to life-saving Aids drugs, a government report says.

    04 August 2014 | BBC
  • Cancer treatment clears two Australian patients of HIV

    Scientists have uncovered two new cases of HIV patients in whom the virus has become undetectable. The patients' virus levels became undetectable after bone-marrow therapy with stem cells.

    20 July 2014 | Nature
  • Three Top Researchers Question Efavirenz Status as First-Line Agent

    Looking at recent evidence, three top clinical investigators question whether the nonnucleoside efavirenz should maintain its rank as a preferred first-line antiretroviral.

    14 July 2014 | International AIDS Society
  • Common HIV Drug May Boost Suicide Risk

    A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.

    02 July 2014 | Web MD
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
  • Lowering toxicity of new HIV drugs predicted to improve life expectancy

    While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals.

    26 June 2014 | EurekAlert
  • Mortality with HIV drops sharply in Georgia after 2004 cART rollout

    Mortality among Georgians with HIV fell by more than half after 2004, when the Eastern European country began providing combination antiretroviral therapy (cART) to everyone in need. Tuberculosis remains a leading cause of death.

    23 June 2014 | International AIDS Society
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.